Professor Stephan Rosenkranz

Organisation / Institute
Department III of Internal Medicine
Cologne University Heart Center

Address

Prof. Stephan Rosenkranz
Department III of Internal Medicine,
Cologne University Heart Center
Kerpener Str. 62
50937 Köln, Germany

stephan.rosenkranz[at]uk-koeln.de

 

 

 

 

Dr. Henrik ten Freyhaus

Organisation / Institute
Department III of Internal Medicine
Cologne University Heart Center

Address

Dr. Henrik ten Freyhaus
Department III of Internal Medicine,
Cologne University Heart Center
Kerpener Str. 62
50937 Köln, Germany

henrik.ten-freyhaus[at]uk-koeln.de

Professor Stephan Rosenkranz / Dr. Henrik ten Freyhaus

Project summary: 

Role of the 6-transmembrane protein Stamp2 in Pulmonary Hypertension

A chronic, low-grade inflammation at key metabolic organs, including adipose tissue, is a hallmark of obesity and contributes to related complications such as insulin resistance. Importantly, both nutrients (such as glucose and lipids) and cytokines are able to activate inflammatory and stress signaling pathways such as JNK and IKK. The impact of nutrients on inflammatory pathways demands the existence of counterregulatory mechanisms to prevent overt inflammation upon physiological fluctuations in nutrient availability. Recently, the six-transmembrane protein of prostate (Stamp)-2 was discovered as a molecule involved in such a role in adipose tissue. Stamp2 expression was regulated by fasting/feeding in mice and Stamp2-deficient mice developed metabolic syndrome and showed macrophage infiltration of visceral adipose tissue. We recently discovered an important role of Stamp2 in macrophages. In these cells, Stamp2 serves as an anti-inflammatory mediator by regulating NADP/NADPH homeostasis. Furthermore, Stamp2-deficiency promotes early atherosclerosis and inflammation within atherosclerotic plaques in mice. Consequently, Stamp2 appears to be an important anti-inflammatory protein in various pathologies. Pulmonary hypertension (PH) is associated with a poor prognosis. Inflammatory processes are critical during initiation and progression of the disease. Thus, the aim of the current proposal is to define the role of Stamp2 in the control of inflammation in the pulmonary vasculature and in PH.

 

 

General Research Interest:

 

Prof. Stephan Rosenkranz

Prof. Stephan Rosenkranz attended the Medical School of the University of Giessen and graduated from there in 1994. His residency at the Department of Cardiology at the University of Cologne from 1995 to 1997 was followed by a post doctoral research fellowship in the laboratory of Prof. Andrius Kazlauskas at Harvard Medical School, Boston, USA, from 1997 to 1999. Thereafter, he continued his medical training at the University Heart Center Cologne and became an independent group leader supervising clinical and experimental research. In 2005 he received the board approval for Internal Medicine, and in 2006 he became an assistant professor at the University Heart Center Cologne receiving the board approvals for Cardiology and Intensive Care Medicine in 2006 and 2011. In 2012 he obtained a position as associate professor at the Department of Cardiology at the University Heart Center Cologne, and furthermore serves as coordinator of the research track “Cardiovascular Disease” at the Medical Faculty of the University of Cologne.

His work has been acknowledged amongst others by the Research Award of the German Heart Foundation in 2000, the Research Award of the German Society for Internal Medicine in 2002, and the Andreas Grüntzig Award of the German Society of Cardiology in 2011.

 

Dr. Henrik ten Freyhaus

Dr. Henrik ten Freyhaus attended the Medical School of the University of Cologne and graduated from there in 2004. His residency in the Department of Cardiology at the University of Cologne from 2004 to 2008 was followed by a position as a post doctoral research fellow in the laboratory of Professor G.S. Hotamisligil at the Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, USA, from 2008 to 2010. Funding was supplied by the German Research Foundation (DFG). Thereafter, he continued his medical training at the University Heart Center in Cologne as a physician and scientific staff member. He received an academic fellowship from the Friedrich-Ebert-Stiftung, and his work in the field of pulmonary hypertension has recently been acknowledged by the research award of the René-Baumgart-Stiftung. In 2012 he received the board approval for Internal Medicine.